

# Index

Note: Page numbers of article titles are in **boldface** type.

## A

- Abbott troponin assays, 64, 69
- Absorbance assays, 172–173
- Acute coronary syndrome, 21–26
  - clinical presentation of, 21–22
  - differential diagnosis of, 67–68
  - electrocardiography for, 22–23
  - markers for, 23–24
  - natriuretic peptides for, 53–54
  - physical examination findings in, 22
  - point-of-care testing for, **75–85**
  - spectrum of, 21
  - treatment of, 24–26
  - troponins for, **59–73**
  - types of, 21
- Acute Shortness of Breath Evaluation (BASEL) study, 48
- Adrenomedullin, 7
- Alere troponin assays, 64
- American College of Medical Genetics, 152
- Analyte, definition of, 182
- Anemia, in heart failure, 18–19
- Aneurysm osteoarthritis syndrome, 146–147
- Aneurysms, thoracic aortic, 145–148
- Angina, unstable. *See* Acute coronary syndrome.
- Angiotensin-converting enzyme inhibitors, for heart failure, 19–20
- Antibodies and autoantibodies, in immunometric assays, 168, 170–173, 178–179
- Antiplatelet agents, for acute coronary syndrome, 24–26
- Antithrombin III deficiency, 150–152
- Aortic stenosis, supraaortic, 149–150
- Apolipoprotein, phospholipase A2 associated with, 120–121
- Apolipoprotein A, polymorphisms of, 124
- Apolipoprotein B/Apolipoprotein AI ratio, 117–118
- Apolipoprotein E, polymorphisms of, 123
- Arachnodactyly, congenital contractural, 148
- Arginine vasopressin, 7
- Arrhythmias, genetics of, 142–145
- Arrhythmogenic right ventricular cardiomyopathy, 142
- Arterial tortuosity syndrome, 147
- Aspartate aminotransferase, for myocardial necrosis, 33–34
- Atherosclerosis, **113–127**
  - formation of, after percutaneous coronary intervention, 105
  - pathogenesis of, 114–115

Atherosclerosis (*continued*)

- risk factors for
  - analytical methods for, 116–118
  - novel biomarkers for, 116–124
- treatment goals for, 115–116

Atrial fibrillation, familial, 145

Atrial natriuretic peptide

- for heart failure, 52
- for myocyte stress, 6

**B**

Background signals, in immunometric assays, 171–172

BASEL (Acute Shortness of Breath Evaluation) study, 48

Beckman troponin assays, 64

Biomarkers

- definition of, 167
- for cardiac disease. *See* Cardiac markers.

Biomarkers in Cardiology Trial, 5–6, 67

Biopsy, for transplant rejection, versus biomarkers, 131–132

Bloch pathway, for cholesterol synthesis, 158

Breathing Not Properly Multinational Study, 47

Brugada syndrome, 144–145

B-type natriuretic peptide and N-terminal pro-B-type natriuretic peptide

- analytical properties of, 45, 47
- assays for, 177
- characteristics of, 169
- for heart failure, 18, 47–52
- for myocyte stress, 6
- physiology of, 44–45

**C**

Calibrator, definition of, 182

Campesterol, absorption and synthesis of, 157–166

Cardiac markers

- after surgery, **99–111**
- commonly in use, 168
- definition of, 167
- for acute coronary syndromes, 21–26, **43–73**
- for atherosclerosis risk factors, **113–127**
- for genetic disease, **137–156**
- for heart failure. *See* Heart failure.
- for hyperlipidemia, **157–166**
- for myocardial necrosis, **31–41, 129–135**
- goals of, 167
- history of, 168
- measurement methods for, **167–185**
- newer, 168
- overview of, **1–14**
- pathophysiology and, 3–10

- point-of-care. *See* Point-of-care testing.
- Cardiac myosin binding protein C, 169
- Cardiac Resynchronization in Heart Failure study, 93
- Cardiac resynchronization therapy, for heart failure, 20
- Cardiac troponins. *See* Troponin(s).
- Cardiomyopathy
  - arrhythmogenic right ventricular, 142
  - dilated, 140–141
  - hypertrophic, 138–140
  - restrictive, 141
- Catecholaminergic polymorphic ventricular tachycardia, 144
- Centaur TnI-Ultra method, for rapid point-of-care testing, **75–85**
- Channelopathies, genetics of, 142–145
- Chest pain
  - in acute coronary syndrome, 21–22
  - point-of-care testing for, **75–85**
- Cholesterol, in cholesterol synthesis, 160
- Cholesterol
  - absorption and synthesis of, **157–166**
    - biomarkers of, 158–162
    - lipid-lowering drugs and, 162–165
  - analytical methods for, 116–118
  - in atherosclerosis formation, 114–115
  - reduction goals for, 115–116
- Christchurch Cardioendocrine Group, 52
- COACH (Coordinating Study Evaluation Outcomes of Advising and Counseling Failure), 92–93
- Coefficient of variance, in immunometric assays, 172
- Congenital contractural arachnodactyly, 148
- Congenital heart defects, 148–150
- Congestive heart failure. *See* Heart failure.
- Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA), 92
- Coordinating Study Evaluation Outcomes of Advising and Counseling Failure (COACH), 92–93
- Copeptin, 5, 7
- CORONA (Controlled Rosuvastatin Multinational Trial in Heart Failure), 92
- Coronary artery bypass graft surgery, myocardial injury after, 102, 106–108
- Coronary artery disease
  - natriuretic peptides for, 53–54
  - risk factors for. *See* Atherosclerosis.
- C-reactive protein
  - for inflammation, 7–8
  - high-sensitivity tests for, 118–120
- Creatine kinase MB
  - characteristics of, 169
  - for acute coronary syndrome, 23–24
  - for cardiac surgery, 106–108
  - for myocardial necrosis, 34–36
  - for percutaneous coronary intervention, 103–105
  - versus troponins, 66
- Creatine phosphokinase, for myocardial necrosis, 34–36

Cummins troponin assay, 61  
Cutoff values, for methodologies, 179–181  
Cystatin C, for kidney dysfunction, 9–10  
Cytokines, for inflammation, 7–8

## D

Dallas Heart Study, 70, 161  
Desmosterol, in cholesterol synthesis, 158, 160–161  
Detection system, in immunometric assays, 172–173  
Dilated cardiomyopathy, 140–141  
Dipeptidyl peptidase, for myocyte stress, 6  
Dissections, thoracic aortic, 145–148  
Diuretics, for heart failure, 20

## E

EARLY-ACS (Early Glycoprotein IIb/IIIa inhibition in Non-ST-Segment Elevation Acute Coronary Syndrome), 69  
Echocardiography, for heart failure, 19  
Ehlers-Danlos syndrome, 146  
Electrocardiography  
    for acute coronary syndrome, 22–23  
    for heart failure, 19  
Emergency department, rapid point-of-care testing in, **75–85**  
Endothelin-1, 7  
Enzyme-linked immunosorbent assays, 172–173  
EPIC-Norfolk study, 161  
Eplerenone, for heart failure, 20  
European Heart Rhythm Association, 152  
Extracellular matrix remodeling, 8–9  
Ezetimibe, actions of, 159, 161–165

## F

Factor V Leiden, 150–152  
Familial atrial fibrillation, 145  
Fibrinolysis, for acute coronary syndrome, 24  
Fibroblast growth factor 23, 10  
Fragmin and fast revascularization during InStability in Coronary artery disease trial, 54  
Framingham Offspring Study, 161  
Framingham Risk Score, 115–116

## G

Galectin-3  
    assays for, 172–173  
    characteristics of, 169  
    for extracellular matrix remodeling, 9  
    for heart failure, 91–94  
Gas chromatography/mass spectrometry, for cholesterol precursors, 159

## Genetics

- of arrhythmias, 142–145
- of cardiomyopathies, 137–142
- of channelopathies, 142–145
- of congenital heart defects, 148–150
- of Marfan-like phenotypes, 145–148
- of pulmonary arterial hypertension, 150
- of thoracic aortic aneurysms and dissections, 145–148
- of thrombophilia, 150–152
- testing guidelines for, 152

Ghent nosology, for Marfan syndrome, 152

GISSI-HF (Gruppo Italiano per lo Studio della Sopravivenza nell'insufficienza Cardiac-Heart Failure) study, 52

Global Use of Strategies to Open Occluded Arteries (GUSTO) trial, 69–70

Glycogen phosphorylase BB5, for myocyte injury, 5

Growth differentiation factor 15, for myocyte stress, 6–7

Gruppo Italiano per lo Studio della Sopravivenza nell'insufficienza Cardiac-Heart Failure (GISSI-HF) study, 52

GUSTO (Global Use of Strategies to Open Occluded Arteries) trial, 69–70

## H

Heart disease, cardiac markers for. *See* Cardiac markers.

Heart failure, 15–21

- classification of, 16
- clinical presentation of, 16–17
- definition of, 15
- diagnostic findings in, 18–19
- galectin-3 in, 91–94
- natriuretic peptides for, 47–52
- physical examination findings in, 17–18
- prognosis for, 50–51
- ST2 for, 88–91
- treatment of, 19–20
  - with preserved ejection fraction, 20

Heart Rhythm Society, 152

Heart-type fatty acid-binding protein, for myocyte injury, 5

3-Hydroxy-3-methyl-glutaryl CoA, 158

Hypertension, pulmonary arterial, 150

Hypertrophic cardiomyopathy, 138–140

Hypoplastic left heart syndrome, 148–150

## I

Immunoassays

- definition of, 182–183
- for natriuretic peptides, 45, 47
- for troponins, 61–65

Immunometric assays, 168, 170–173, 183

Implantable cardioverter-defibrillator, for heart failure, 20

Improved Management of Patients With Congestive Heart Failure (IMPROVE-CHF) study, 48–49

Inflammation, 7–8

Interpretation, of results, 179–181

## J

Jervell and Lange-Nielsen syndrome, 144

Jugular venous pressure, in heart failure, 17–18

JUPITER (Justification for the use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin), 7–8, 118–120

## K

Kandutsch-Russell pathway, for cholesterol synthesis, 158

Katus troponin assay, 61

Kidney dysfunction, in heart failure, 9–10, 50

Klotho, 10

## L

Lactate dehydrogenase

for acute coronary syndrome, 24

for myocardial necrosis, 36

Lathosterol, absorption and synthesis of, 157–166

Left ventricular non-compaction, 141

Limit of detection, definition of, 183

Limit of quantification, 183

Lipocalin, for kidney dysfunction, 10

Lipoprotein(s)

analytical methods for, 116–118

genetics of, 123

in atherosclerosis formation, 114–115

low-density, oxidized, myeloperoxidase and, 121–122

Lipoprotein (A), 122–123

Liquid chromatography tandem mass spectrometry, for cholesterol precursors, 159

Loeys-Dietz syndrome, 147–148

Long QT syndrome, 142–144

Luminex system, 174–175

## M

Marfan-like phenotypes, 145–148, 152

Matrix metalloproteinase

for extracellular matrix remodeling, 9

for vulnerable plaque, 8

Metabolomics, 10

Methodologies, for cardiac markers, **167–185**

immunometric assays, 168.170–173

interpretive limitations of, 179–181

multiplex assays, 174–176

point-of-care testing, 173–174

technical limitations of, 176–179

terminology of, 182–184

Mevalonate, in cholesterol synthesis, 158

- β2-Microglobulin, for kidney dysfunction, 10
- MicroRNAs, 11
- Multimarker panels, for myocardial necrosis, 36–38
- Multiplex assays, 174–176
- Myeloperoxidase
  - for oxidative stress, 8
  - for vulnerable plaque, 8
  - oxidized low-density lipoprotein and, 121–122
- Myocardial infarction. *See also* Acute coronary syndrome.
  - definition of, 65–66, 100–102
  - percutaneous coronary interventions for, 101–105
  - surgery for, 106–108
  - types of, 100
- Myocardial necrosis, cardiac markers for, **31–41**
  - chronology of, 33–40
  - ideal, 32–33
- Myocarditis, **129–135**
- Myocarditis Treatment Trial, 130–131
- Myocyte(s), troponin release from, 60–61
- Myocyte injury, 3–6
- Myocyte stress, 6–7
- Myoglobin, for myocardial necrosis, 36

## N

- Nanosphere troponin assay, 65
- National Cholesterol Education Program, 115–116, 161
- Natriuretic peptides. *See also specific types.*
  - analytical properties of, 45, 47
  - for acute coronary syndrome, 24, 53–54
  - for coronary artery disease, 53–54
  - for heart failure, 18, 47–52
  - for myocyte stress, 6–7
  - physiology of, 44–46
- Necrosis, myocardial, **31–41**
- Neo-atherosclerosis, after percutaneous coronary intervention, 105
- Neointimal hyperplasia, in percutaneous coronary intervention, 104
- Neurohormones, 7
- Neutrophil gelatinase-associated lipocalin, for kidney dysfunction, 10
- Niemann-Pick C1 like transporter, 158–159
- Nonspecific background, in immunometric assays, 171–172
- NSTE-ADS (Non-ST-Elevation Acute Coronary Syndrome), 69
- N-terminal pro-B-type natriuretic peptide. *See* B-type natriuretic peptide and N-terminal pro-B-type natriuretic peptide.
- Nuclear magnetic resonance spectroscopy, for lipoproteins, 118

## O

- Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure trial, 50–51
- Oxidative stress, 8

**P**

- Panels, for myocardial necrosis, 36–38
- Patent ductus arteriosus, 148–150
- Pentraxin 3, for vulnerable plaque, 8
- Percutaneous coronary interventions, myocardial injury after, 101–105
- Phospholipase A2, apolipoprotein associated with, 120–121
- Placental growth factor, for vulnerable plaque, 8
- Plaque, vulnerable, 8
- Point-of-care testing
  - for chest pain, **75–85**
  - for myocardial necrosis, 38
  - methodologies for, 173–174
- Precision, 183
- Pregnancy-associated plasma protein A, for vulnerable plaque, 8
- PRIDE (ProBNP Investigation of Dyspnea in the Emergency Department) study, 47–48, 89–90, 92
- Proadrenomedullin, 7
- Pro-arginine vasopressin, 7
- ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) study, 47–48, 89–90, 92
- ProBNP Outpatient Tailored Chronic HG Therapy study, 52
- Procollagen 1, for extracellular matrix remodeling, 9
- Proprotein convertase subtilin/kinexin, 124
- PROSPER study, 161
- PROTECT Study, 93
- Protein C deficiency, 150–152
- Protein S deficiency, 150–152
- Prothrombin polymorphisms, 150–152
- Pulmonary arterial hypertension, 150
- Pulmonary congestion, in heart failure, 18

**Q**

- Quanterix troponin assay, 65

**R**

- Radiography, for heart failure, 19
- Radiometer troponin assays, 64
- Rancho Bernardo Study, 69
- Restrictive cardiomyopathy, 141
- Roche troponin assays, 64
- Romano-Ward syndrome, 142–144
- Rule Out Myocardial Infarction using Computer Assisted Tomography trial, 53

**S**

- Sandwich immunoassays, for troponin, 63–65
- Sensitivity, of methodologies, 176–177, 183–184



- SEPIA-ACS1-TIMI- 42 (Study of Otamixaban Versus Unfractionated Heparin and Eptifibatide in Non-ST Elevation Acute Coronary Syndrome), 69
- Septal defects, congenital, 148–150
- Short QT syndrome, 144
- Siemens troponin assays, 64–65
- Signal generating system, in immunometric assays, 168, 170
- Singulex cTNI assay, 63, 70
- $\beta$ -Sitosterol, absorption and synthesis of, 157–166
- Sitosterolemia, 161
- Small molecules, 10
- Sortilin gene, in lipid metabolism, 123
- Specificity, of methodologies, 177, 183–184
- Specimen-specific interferences, with assays, 178–179
- Spirolactone, for heart failure, 25720
- Squalene, absorption and synthesis of, 158, 160
- ST2
  - assays for, 173
  - characteristics of, 169
  - for heart failure, 88–91
  - for myocyte stress, 6
- Statins, actions of, 158–159, 161–165
- Stent placement, myocardial injury after, 101–105
- Stratus troponin assay, 61
- Study of Otamixaban Versus Unfractionated Heparin and Eptifibatide in Non-ST Elevation Acute Coronary Syndrome (SEPIA-ACS1-TIMI- 42), 69
- Supravalvular aortic stenosis, 149–150

## T

- Tetralogy of Fallot, 148–150
- Thoracic aortic aneurysms and dissections, 145–148
- Thrombophilia, 150–152
- Tissue inhibitors of metalloprotein, for extracellular matrix remodeling, 9
- Transaminase, for heart failure, 18
- Transplantation, cardiac, rejection of, 131–132
- Trimethylamine N-oxide, 10
- Troponin(s), **59–73**
  - as diagnostic tool, 65–68
  - as preferred biomarker, 66
  - as prognostic tool, 68–70
  - assays for, 61–65
  - characteristics of, 169
  - diagnostic cutoff value for, 66–67
  - for cardiac surgery, 106–108
  - for myocarditis, 129–134
  - for non myocardial infarction conditions, 67–68
  - for patients without acute coronary syndrome or heart failure, 133–134
  - for percutaneous coronary intervention, 103–105
  - functions of, 60–61
  - genes of, 60
  - highly-sensitive assays for, 62–65

Troponin(s) (*continued*)

release of, 60–61

structures of, 60–61

Troponin C, structure of, 60

Troponin I. *See also* Troponin(s).

for acute coronary syndrome, 23–24

for myocardial necrosis, 38–40

for myocyte injury, 3–5

in point-of-care testing, **75–85**Troponin T. *See also* Troponin(s).

for acute coronary syndrome, 23–24

for myocardial necrosis, 38–40

for myocyte injury, 3–5

**V**

Val-HeFT (Valsartan Heart Failure Trial), 50–51, 92

Vasopressin, 7

Vulnerable plaque, 8